당뇨병성 위마비 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별(등급 2, 등급 3), 약물 종류별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Diabetic Gastroparesis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Grade 2, Grade 3), By Drug Class, By Route of Administration, By Distribution Channel By Region and Competition, 2020-2030F
상품코드:1714465
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
당뇨병성 위마비 치료 세계 시장 규모는 2024년 28억 9,000만 달러로 2030년까지 연평균 3.23%의 안정적인 성장이 예상됩니다.
이 시장은 당뇨병의 합병증인 위 배출 지연을 특징으로 하는 당뇨병성 위마비 관리에 대응하고 있습니다. 당뇨병 환자가 전 세계적으로 급증함에 따라 위 마비 유병률도 증가하여 효과적인 치료 옵션에 대한 수요가 증가하고 있으며, Frontiers 저널의 2025년 연구에 따르면 당뇨병 환자의 5%에서 12%까지 위장 증상이 영향을 미치고 있어 개선된 진단 및 치료 솔루션의 필요성이 강조되고 있습니다. 개선의 필요성이 강조되고 있습니다. 이 시장은 의약품, 식이요법, 의료기기에 걸쳐 있으며, 주요 제품으로는 소화촉진제, 구토방지제, 영양보충제 등이 있습니다. 이러한 치료법은 메스꺼움, 구토, 복통, 소화불량 등의 증상을 완화하고 궁극적으로 환자의 삶의 질을 향상시키는 것을 목표로 합니다. 환자 중심의 치료와 혁신적인 치료법이 강조되면서, 이 진화하는 헬스케어의 전망은 계속 변화하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
28억 9,000만 달러
시장 규모 : 2030년
34억 7,000만 달러
CAGR : 2025-2030년
3.23%
급성장 부문
경구
최대 시장
북미
시장 촉진요인
당뇨병 유병률 증가
주요 시장 과제
제한된 치료 옵션
주요 시장 동향
맞춤형 의료
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계의 당뇨병성 위마비 치료 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
유형별(등급 2(대상성 위마비), 등급 3(위부전))
약물 종류별(소화관 운동 촉진제, 항구토제, 항히스타민제, 기타)
투여 경로(경구, 비경구, 경비)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2024년)
시장 맵
유형별
약물 종류별
투여 경로별
유통 채널별
지역별
제5장 아시아태평양의 당뇨병성 위마비 치료 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
유형별
약물 종류별
투여 경로별
유통 채널별
국가별
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제6장 유럽의 당뇨병성 위마비 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제7장 북미의 당뇨병성 위마비 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제8장 남미의 당뇨병성 위마비 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제9장 중동 및 아프리카의 당뇨병성 위마비 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
이집트
제10장 시장 역학
성장 촉진요인
과제
제11장 시장 동향과 발전
최근 동향
제품 출시
인수합병
제12장 세계의 당뇨병성 위마비 치료 : SWOT 분석
제13장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제14장 경쟁 구도
ANI Pharmaceuticals, Inc.
Evoke Pharma
Janssen Pharmaceutica N.V
Teva Pharmaceuticals Inc.
Pfizer Inc.
Salix Pharmaceuticals, Inc.
Allergan
Novartis AG
SCHWITZ BIOTECH
Wellona Pharma
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
The Global Diabetic Gastroparesis Treatment Market was valued at USD 2.89 billion in 2024 and is projected to witness steady growth at a CAGR of 3.23% through 2030. This market addresses the management of diabetic gastroparesis, a complication of diabetes marked by delayed stomach emptying. As diabetes cases surge globally, so too does the prevalence of gastroparesis, intensifying the demand for effective treatment options. According to a 2025 study in Frontiers, gastrointestinal symptoms affect 5% to 12% of diabetic individuals, highlighting the need for improved diagnostic and treatment solutions. The market spans pharmaceuticals, dietary modifications, and medical devices, with key products including prokinetic agents, antiemetics, and nutritional support tools. These treatment modalities aim to alleviate symptoms like nausea, vomiting, abdominal pain, and indigestion, ultimately enhancing patients' quality of life. The growing emphasis on patient-centric care and innovative therapies continues to reshape this evolving healthcare landscape.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.89 Billion
Market Size 2030
USD 3.47 Billion
CAGR 2025-2030
3.23%
Fastest Growing Segment
Oral
Largest Market
North America
Key Market Drivers
Rising Prevalence of Diabetes
A significant driver of the Global Diabetic Gastroparesis Treatment Market is the escalating prevalence of diabetes worldwide. Both type 1 and type 2 diabetes have reached alarming levels, with WHO data showing an increase in global diabetes cases from 200 million in 1990 to 830 million in 2022. Among these individuals, approximately 20% experience diabetic gastroparesis due to nerve damage affecting stomach motility. The link between chronic hyperglycemia and gastrointestinal complications means that as diabetes becomes more widespread, so does the incidence of gastroparesis. Notably, in 2022, 14% of adults aged 18+ had diabetes, and over half of diabetic adults aged 30+ remained untreated-particularly in low- and middle-income countries. This growing diabetic population continues to fuel demand for effective treatment options that address gastroparesis symptoms and prevent further complications, positioning this segment as a critical focus within global healthcare.
Key Market Challenges
Limited Treatment Options
Despite progress in managing diabetic gastroparesis, the market still struggles with limited treatment options. The primary drugs used-prokinetic agents and antiemetics-offer only partial relief and are not effective for all patients. This narrow pharmaceutical toolkit leaves many individuals without adequate solutions for persistent symptoms like nausea, bloating, and abdominal pain. The lack of diverse and universally effective medications restricts clinicians' ability to personalize treatment and achieve consistent patient outcomes. Moreover, when standard therapies fail, patients often endure ongoing discomfort, leading to diminished quality of life. Healthcare providers also face difficulty managing a condition that lacks sufficient therapeutic diversity. Addressing this challenge requires greater investment in R&D to develop novel drugs, improve existing formulations, and introduce more targeted treatment approaches capable of catering to a wider range of patient responses.
Key Market Trends
Personalized Medicine
Personalized medicine is gaining momentum in the Global Diabetic Gastroparesis Treatment Market as a transformative trend focused on tailoring treatments to individual patient needs. Since diabetic gastroparesis presents differently across patients, personalization enables more precise and effective symptom management. By factoring in each patient's medical history, symptom severity, and therapeutic response, healthcare providers can optimize treatment strategies-choosing between drug classes like prokinetic agents, antiemetics, or alternative therapies as appropriate. This customized approach improves efficacy, reduces side effects, and enhances patient satisfaction. The rise of personalized medicine underscores a shift toward targeted care, where data-driven decisions and individualized protocols support better health outcomes and address the variability inherent in diabetic gastroparesis cases.
Key Market Players
ANI Pharmaceuticals, Inc.
Evoke Pharma
Janssen Pharmaceutica N.V
Teva Pharmaceuticals Inc.
Pfizer Inc.
Salix Pharmaceuticals, Inc.
Allergan
Novartis AG
SCHWITZ BIOTECH
Wellona Pharma
Report Scope:
In this report, the Global Diabetic Gastroparesis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Diabetic Gastroparesis Treatment Market, By Type:
Grade 2 (Compensated Gastroparesis)
Grade 3 (Gastric Failure)
Diabetic Gastroparesis Treatment Market, By Route of Administration:
Oral
Parenteral
Nasal
Diabetic Gastroparesis Treatment Market, By Drug Class:
Gastroprokinetic Agents
Antiemetic Agents
Antihistamines
Others
Diabetic Gastroparesis Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Diabetic Gastroparesis Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Gastroparesis Treatment Market.
Available Customizations:
Global Diabetic Gastroparesis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Diabetic Gastroparesis Treatment Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Grade 2(Compensated Gastroparesis), Grade 3(Gastric Failure))
4.2.2. By Drug Class (Gastroprokinetic Agents, Antiemetic Agents, Antihistamines, Others)
4.2.3. By Route of Administration (Oral, Parenteral, Nasal)
4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.5. By Region
4.2.6. By Company (2024)
4.3. Market Map
4.3.1. By Type
4.3.2. By Drug Class
4.3.3. By Route of Administration
4.3.4. By Distribution Channel
4.3.5. By Region
5. Asia Pacific Diabetic Gastroparesis Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Drug Class
5.2.3. By Route of Administration
5.2.4. By Distribution Channel
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Diabetic Gastroparesis Treatment Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Drug Class
5.3.1.2.3. By Route of Administration
5.3.1.2.4. By Distribution Channel
5.3.2. India Diabetic Gastroparesis Treatment Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Drug Class
5.3.2.2.3. By Route of Administration
5.3.2.2.4. By Distribution Channel
5.3.3. Australia Diabetic Gastroparesis Treatment Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Drug Class
5.3.3.2.3. By Route of Administration
5.3.3.2.4. By Distribution Channel
5.3.4. Japan Diabetic Gastroparesis Treatment Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Drug Class
5.3.4.2.3. By Route of Administration
5.3.4.2.4. By Distribution Channel
5.3.5. South Korea Diabetic Gastroparesis Treatment Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Drug Class
5.3.5.2.3. By Route of Administration
5.3.5.2.4. By Distribution Channel
6. Europe Diabetic Gastroparesis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Class
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Diabetic Gastroparesis Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Class
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Germany Diabetic Gastroparesis Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Class
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Spain Diabetic Gastroparesis Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Class
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
6.3.4. Italy Diabetic Gastroparesis Treatment Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Drug Class
6.3.4.2.3. By Route of Administration
6.3.4.2.4. By Distribution Channel
6.3.5. United Kingdom Diabetic Gastroparesis Treatment Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Drug Class
6.3.5.2.3. By Route of Administration
6.3.5.2.4. By Distribution Channel
7. North America Diabetic Gastroparesis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Type
7.2.3. By Distribution Channel
7.2.4. By Route of Administration
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Diabetic Gastroparesis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Class
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Diabetic Gastroparesis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Class
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Diabetic Gastroparesis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Class
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. South America Diabetic Gastroparesis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Type
8.2.3. By Distribution Channel
8.2.4. By Route of Administration
8.2.5. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Diabetic Gastroparesis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Class
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Argentina Diabetic Gastroparesis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Class
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Colombia Diabetic Gastroparesis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Class
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
9. Middle East and Africa Diabetic Gastroparesis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Diabetic Gastroparesis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug Class
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. Saudi Arabia Diabetic Gastroparesis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. UAE Diabetic Gastroparesis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug Class
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. Egypt Diabetic Gastroparesis Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Drug Class
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Diabetic Gastroparesis Treatment: SWOT Analysis
